Annexin A1 and the regulation of innate and adaptive immunity

Felicity N E Gavins, Michael John Hickey

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Inflammation is the body s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.
Original languageEnglish
Article number354
Number of pages11
JournalFrontiers in Immunology
Volume3
DOIs
Publication statusPublished - 27 Nov 2012

Cite this

@article{17e2f6cced20484ca687b388dc3d4a64,
title = "Annexin A1 and the regulation of innate and adaptive immunity",
abstract = "Inflammation is the body s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.",
author = "Gavins, {Felicity N E} and Hickey, {Michael John}",
year = "2012",
month = "11",
day = "27",
doi = "10.3389/fimmu.2012.00354",
language = "English",
volume = "3",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media",

}

Annexin A1 and the regulation of innate and adaptive immunity. / Gavins, Felicity N E; Hickey, Michael John.

In: Frontiers in Immunology, Vol. 3, 354, 27.11.2012.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Annexin A1 and the regulation of innate and adaptive immunity

AU - Gavins, Felicity N E

AU - Hickey, Michael John

PY - 2012/11/27

Y1 - 2012/11/27

N2 - Inflammation is the body s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.

AB - Inflammation is the body s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A(4), is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23230437

U2 - 10.3389/fimmu.2012.00354

DO - 10.3389/fimmu.2012.00354

M3 - Article

VL - 3

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 354

ER -